Results 211 to 220 of about 5,797,712 (321)
Network Localization of Fatigue in Multiple Sclerosis
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo +12 more
wiley +1 more source
Generalizable Molecular Switch Designs for <i>In Vivo</i> Continuous Biosensing. [PDF]
Saunders J, Thompson IAP, Soh HT.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism.
James M. Murphy +22 more
semanticscholar +1 more source
Exosome-mediated miRNA delivery: a molecular switch for reshaping neuropathic pain therapy. [PDF]
Wei Z +6 more
europepmc +1 more source
Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein. [PDF]
Geng Q +9 more
europepmc +1 more source
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Nuclear paxillin functions as a molecular switch for alternative splicing in neurons during a critical period of brain development. [PDF]
Chu CH +10 more
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
An Electrochromic Tristable Molecular Switch.
Junling Sun +7 more
semanticscholar +1 more source

